SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. engages in the design, manufacture, and launch of rockets and spacecrafts. It provides satellite communication services. The company was founded by Elon Reeve Musk on March 14, 2002 and is headquartered in Hawthorne, CA.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently trending as investors debate the massive valuation of its record-breaking IPO, with the community split between long-term bullish optimism for space infrastructure and bearish warnings regarding overvaluation and potential liquidity risks. While some retail traders are aggressively accumulating shares to hold for the future, others are actively scouting for entry points below IPO levels, waiting for the initial hype and volatility to settle.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Roku is seeing high volatility and intense community speculation following a recent report that the company is exploring a potential sale to a major media entity. Investors are actively debating the viability of a buyout versus a standalone growth strategy, with many weighing the companys platform dominance and recent profitability against ongoing market skepticism and competitive pressures.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is seeing high volatility as capital rotates into the major SpaceX IPO, leading investors to debate whether this decline is a temporary liquidity shakeout or a broader sector de-rating. The community remains focused on upcoming launch catalysts and the stock's long-term competitive position versus Starlink, with many viewing the sharp price pullback as a potential buying opportunity.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as investors digest the DOJ's approval of its high-stakes acquisition of Warner Bros. Discovery, while the community intensely debates the potential for a mid-July deal closure and the impact of looming antitrust challenges from several U.S. states. The conversation is heavily focused on whether this merger will serve as the necessary catalyst to drive the share price upward or if ongoing regulatory hurdles and debt concerns will continue to suppress valuation.

Entrepreneurshares Series Trust - ERShares Private-Public Crossover ETF

The ERShares Private-Public Crossover ETF (XOVR) is trending as investors debate its structure and valuation in relation to its significant exposure to SpaceX. While some community members are frustrated by the fund's recent price stagnation despite SpaceX's growth, others view it as an accessible, liquid entry point for pre-IPO space exposure compared to more volatile alternatives.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors react to the launch of its midsize R2 SUV, sparking intense community debate over high lease pricing and the company's long-term profitability. While bullish traders point to strong demand and potential mass-market scaling, many are actively expressing frustration over recent stock volatility and the lack of aggressive production updates from leadership.

Tidal Trust II - Defiance Daily Target 2X Short ASTS ETF

ASTN is seeing significant volatility as traders leverage the ETF to play against the momentum of ASTS, which many investors view as a highly volatile meme stock. The community remains deeply divided, with bearish traders utilizing the 2X inverse ETF to bet on a correction while long-term bulls continue to debate the stock's valuation and potential for further gains.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech 100 is experiencing significant volatility and downward pressure as investors rotate out of the fund to pursue direct exposure to the upcoming SpaceX IPO, which has triggered widespread selling despite the fund's heavy concentration in high-growth private tech assets. The community remains deeply divided, with some investors aggressively adding to positions on the belief that current market prices trade at a steep discount to the fund's true net asset value, while others are frustrated by management's dilution through share offerings and a lack of communication regarding the fund's underlying valuation.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF is trending as investors react to the historic NYSE uplisting of Trulieve and broader sector anticipation surrounding upcoming DEA hearings. While the community is actively debating the impact of these regulatory catalysts and potential institutional inflow, ongoing price volatility remains a major talking point as traders navigate market manipulation concerns and shifting max pain levels.

ROAM Token

The ROAM community is generating significant buzz around the intersection of its decentralized connectivity network, eSIM travel utility, and a new AI-driven creative challenge. Supporters are highlighting the project's real-world infrastructure growth and its transition into an AI-ready ecosystem, while debate continues regarding its marketing strategy and long-term token utility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About Sarepta Therapeutics (SRPT) Rating Upgrade to Buy

Sarepta Therapeutics (SRPT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

SRPT vs. ARGX: Which Stock Is the Better Value Option?

Why Is Sarepta Therapeutics (SRPT) Down 19.9% Since Last Earnings Report?

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sarepta Therapeutics to Participate in Upcoming Investor Conferences

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following investor conferences in June: Goldman Sachs 47th Annual Global Healthcare Conference Fireside chat: Monday, June 8, at 10:40...

The Biotech Supercycle Is Here: Retatrutide, VERVE-102, NEO100, and More Set to Transform Medicine

Biotechnology investors are entering one of the most catalyst-heavy clinical cycles in years as a wave of Phase 2 and Phase 3 programs begins reshaping expectations across obesity, oncology, gene editing, autoimmune disease, and neurological disorders. $LLY, $NVO, $NTHI, $BAC, $STT, $BCS, $IMVT, $SRPT, $MRNA, $CRSP

KROS Turns to Next Wave of TGF-Beta Muscle Therapies

Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.

Should You Buy KROS After Q1 Miss and Takeda Deal Reset?

Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.

KROS Stock Guide to Rinvatercept in DMD and ALS for 2026

Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.

Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) Stock

Why Elevidys Matters For Sarepta Therapeutics Inc (SRPT) Stock...

Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the RBC Capital...

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

SRPTSarepta Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SRPT News